- Home
- A-Z Publications
- Current Cancer Therapy Reviews
- Previous Issues
- Volume 11, Issue 3, 2015
Current Cancer Therapy Reviews - Volume 11, Issue 3, 2015
Volume 11, Issue 3, 2015
-
-
Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Authors: A-Rum Yoon, Sung W. Kim and Chae-Ok YunOncolytic adenoviruses (Ad) that selectively replicate in cancer cells are emerging as a promising new modality for cancer treatment. The most attractive feature of oncolytic Ad is its ability to destroy cancer cells through a distinctive and unique function in which the virus selectively replicates and destroys tumors by cell lysis, a function that no anti-cancer drugs can mimic. Moreover, coupling the lytic function of onc Read More
-
-
-
Infectivity Selective Adenovirus Based on High-throughput Adenoviral Ligand Library Screening
More LessAn ultimate goal of the developers of cancer genetherapy/virotherapy is to develop a device enabling systemic treatment of the patients with advanced or spread diseases. The targeting at the level of infection, which can define the initial distribution following intravenous administration, is considered to be the most important for realization of systemic therapy. Adenovirus which has very high in vivo transduction efficiency is Read More
-
-
-
New Generation of Oncolytic Herpes Virus
Authors: Hiroshi Fukuhara and Tomoki TodoOncolytic virus therapy has recently been recognized as a promising new treatment option for cancer. The strategy is to use genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells, without harming normal cells. Herpes simplex virus type 1 (HSV-1) has been well studied and has many advantages for the use in cancer therapy, making it the mainstay of current clinical trials of oncolyt Read More
-
-
-
Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Authors: Toshiyoshi Fujiwara, Shunsuke Kagawa and Hiroshi TazawaA multidisciplinary approach of combining surgery, chemotherapy and radiotherapy has remained the accepted standard management for various types of human cancer. However, many new treatment options have recently become available, including molecular targeted therapies, immunotherapies and oncolytic virotherapies. Replication-selective tumor- specific viruses have been designed to induce virus-mediated Read More
-
-
-
Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
More LessRecently, substantial attention has been focused on cancer treatments using oncolytic viruses, which may result in a paradigm shift in conventional cancer therapy through the use of these viruses either alone or in combination with other therapeutics. Thus far, the cancer-killing mechanism of oncolytic viruses has been dependent on selective viral replication in cancer cells. However, UV-irradiated Sendai virus particles (hemag Read More
-
Volumes & issues
-
Volume 21 (2025)
-
Volume 20 (2024)
-
Volume 19 (2023)
-
Volume 18 (2022)
-
Volume 17 (2021)
-
Volume 16 (2020)
-
Volume 15 (2019)
-
Volume 14 (2018)
-
Volume 13 (2017)
-
Volume 12 (2016)
-
Volume 11 (2015)
-
Volume 10 (2014)
-
Volume 9 (2013)
-
Volume 8 (2012)
-
Volume 7 (2011)
-
Volume 6 (2010)
-
Volume 5 (2009)
-
Volume 4 (2008)
-
Volume 3 (2007)
-
Volume 2 (2006)
-
Volume 1 (2005)
Most Read This Month
Article
content/journals/cctr
Journal
10
5
false
en
